Literature DB >> 10866344

Biology and treatment of malignant glioma.

M D Prados1, V Levin.   

Abstract

Malignant gliomas are a heterogeneous group of tumors that are associated with significant morbidity and mortality. The development of the malignant phenotype is the result of a complex series of events that influence gene expression, angiogenesis, and invasion and favor the growth of tumor cells. Currently, the management of malignant glioma consists of symptom control and cytoreduction with a combination of surgery, radiation therapy, and chemotherapy. However, there is no satisfactory regimen available for adjuvant or salvage chemotherapy for these neoplasms. An overview of the biologic mechanisms, grading systems, and treatment options for anaplastic astrocytoma and glioblastoma multiforme is presented.

Entities:  

Mesh:

Year:  2000        PMID: 10866344

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  58 in total

1.  Altering DNA base excision repair: use of nuclear and mitochondrial-targeted N-methylpurine DNA glycosylase to sensitize astroglia to chemotherapeutic agents.

Authors:  Jason F Harrison; Mikael L Rinne; Mark R Kelley; Nadiya M Druzhyna; Glenn L Wilson; Susan P Ledoux
Journal:  Glia       Date:  2007-11-01       Impact factor: 7.452

2.  Adenoviral-mediated gene transfer into the canine brain in vivo.

Authors:  Marianela Candolfi; Kurt M Kroeger; G Elizabeth Pluhar; Josee Bergeron; Mariana Puntel; James F Curtin; Elizabeth A McNiel; Andrew B Freese; John R Ohlfest; Peter Moore; Pedro R Lowenstein; Maria G Castro
Journal:  Neurosurgery       Date:  2007-01       Impact factor: 4.654

3.  Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase Cdelta/c-Src pathways in glioblastoma cells.

Authors:  Samson Amos; Patrick M Martin; Gregory A Polar; Sarah J Parsons; Isa M Hussaini
Journal:  J Biol Chem       Date:  2004-12-23       Impact factor: 5.157

4.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

5.  Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes.

Authors:  Sabine Spiegl-Kreinecker; Johanna Buchroithner; Leonilla Elbling; Elisabeth Steiner; Gabriele Wurm; Angelika Bodenteich; Johannes Fischer; Michael Micksche; Walter Berger
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

6.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

Review 7.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.

Authors:  Fabian Baumann; Miroslava Bjeljac; Spyros S Kollias; Brigitta G Baumert; Sebastian Brandner; Valentin Rousson; Yasuhiro Yonekawa; René L Bernays
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors.

Authors:  Jing Zhang; Bing Liu; Xingpeng Jiang; Huizhi Zhao; Ming Fan; Zhenjie Fan; J Jack Lee; Tao Jiang; Tianzi Jiang; Sonya Wei Song
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

10.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.